Cardiorenal Benefit of Tirzepatide in Type 1 Diabetes: A Case Report

Abstract Patients with type 1 diabetes (T1D) who are obese are at risk of cardiovascular disease, renal diseases, and other complications. Unfortunately, there is currently no cure for T1D, necessitating individuals with this condition to rely on lifelong insulin therapy. Tirzepatide, a dual-acting glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist, has recently been approved for treating type 2 diabetes. We report the case of a 38-year-old male who presented with T1D, stage 2 chronic kidney disease, obesity, and other comorbidities. He was prescribed tirzepatide 2.5 mg initially, followed by titration up to 5 mg. A significant reduction in blood glucose levels, weight, and microalbumin levels was observed. Additionally, the systolic blood pressure level was also seen to improve. These results highlight new indications of tirzepatide in managing T1D and obesity. However, further studies are warranted to explore its efficacy and safety in patients with T1D.